Obtained product was used as the heterogeneous oxidant of As(III) in aqueous solutions. The polymer’s oxidizing capacity, determined as part

of the batch studies, amounted to 193.29 mg As(III) g(-1) (pH=7.7) and 206.03 mg As(III) g(-1) (pH=2.0). The suitability of the redox polymer for long-lasting operation in the aqueous environment was confirmed in the column study conducted using a solution with a concentration of 10 mg As(III) dm(-3) at a flow rate of 6 bed volumes (BV) h(-1). The concentration of As(III) in the effluent reached the value of 0.01 mg As(III) dm(-3) only after 8 weeks of continuous operation when 7930 BV of the solution had passed through the bed. (c) 2014 CYT387 cell line Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2015, MDV3100 132, 41552.”
“Background: The aim of this study was to develop and perform the 3D finite element analysis of a femoral head interior supporting device (FHISD). Material/Methods: The 3D finite element

model was developed to analyze the surface load of femoral head and analyze the stress and strain of the femoral neck, using the normal femoral neck, decompressed bone graft, and FHISD-implanted bone graft models. Results: The stress in the normal model concentrated around the femoral calcar, with displacement of 0.3556 +/- 0.1294 mm. In the decompressed bone graft model, the stress concentrated on the femur calcar and top and lateral sides of femoral head, with the displacement larger

than the normal (0.4163 +/- 0.1310 mm). In the FHISD-implanted bone graft model, the stress concentrated on the segment below the lesser trochanter superior to the femur, with smaller displacement than the normal (0.1856 +/- 0.0118 mm). Conclusions: FHISD could effectively maintain MI-503 clinical trial the biomechanical properties of the femoral neck.”
“Asulacrine (9-[(2-methoxy-4-methylsulphonylamino)phenyl amino]-N,5-dimethyl-4-acridinecarboxamide), an analogue of the antileukaemia drug arnsacrine, has high antitumour activity in mice and has also shown clinical activity. A simple method is described for the quantitation of asulacrine in plasma by liquid chromatography. Chromatographic separation was achieved on a reversed phase C 18 column (250 mm x 4.6 mm, particle size 5 mu m, Gemini) using isocratic elution (acetonitrile and 0.01 M sodium acetate buffer pH 4.0, 45/55, v/v) at a flow rate of 1 ml/min. Asulacrine and internal standard (the ethylsulphonanilide analogue) were measured using UV detection at 254 nm. The total chromatographic run-time was 8 min with asulacrine and internal standard eluting at similar to 4.7 and similar to 6.5 min, respectively. Limit of quantification was 0.1 mu g/ml. The linearity range of the method was 0.1-10 mu g/ml (r(2) = 0.9995). Mean recoveries from plasma were 100-105%.